NovaMedica and Skolkovo Foundation Sign Agreement to Build R&D center

Moscow, Russia– February, 04, 2014 – NovaMedica Innotech, R&D unit of NovaMedica, a Russian pharmaceutical resident company of the Skolkovo Innovation Center, and Skolkovo Foundation signed the agreement to collaborate in building R&D center on the territory of Skolkovo Technopark.

Implementation of NovaMedica’s portfolio product development projects, technology transfer for the purposes of its pharmaceutical plant in Kaluga are among the primary tasks of the NovaMedica research center. Moreover, the production of clinical trial samples of pharmaceutical products required for the registration of new products and technologies in Russia is anticipated there.

The research center is assumed to encompass chemical, biochemical, analytical, pharmaceutical laboratories and a facility for pilot production of pharmaceutical products with an initial area of 500 square meters to be prospectively extended up to 2 000 square meters. Operations of the center are projected to begin in 2015.

At present, the Company’s product portfolio includes a number of GI, ophthalmology, pain management products and technologies as well as several own development projects to be continued in Russia under a new NovaMedica Innotech R&D center. With its major focus on product portfolio creation the Company is in hot pursuit of new innovative products to be marketed in Russia.

“This is a remarkable event for the Biomedical Technologies Cluster because the first resident of the Cluster has secured its intentions via locating its large research laboratory on the territory of the Technopark, - said Kirill Kaem, Executive Director of Biomedical Technologies Cluster of Skolkovo Foundation. “NovaMedica Innotech research center will, indeed, contribute to the development of infrastructure of the Skolkovo Innovation Center”. We hope that many other biomed startups will follow the lead and at the end of the day Technopark will be full of best-in-class laboratories to become a platform for local biopharmaceuticals”.

“We appreciate new research opportunities to be provided in Skolkovo Technopark and are excited to  further support our developments in R&D field in the Russian “Silicon Valley”, said Mikhail Getman, VP, R&D and Regulatory Affairs of NovaMedica. “When siting our R&D laboratory in Skolkovo Innovation Center, we were guided not only by an optimal solution for innovative pharmaceutical products to be developed and marketed Russia. Hopefully, this laboratory will be a basis for cooperation with resident companies developing cutting edge products and technologies in Russia and for participation in educational projects and, finally, it will help us to contribute to the development of a new R&D infrastructure of the local pharmaceutical industry”.

For reference:

NovaMedica

NovaMedica is a Russian pharmaceutical company established in 2012 by DRI Holdings Limited, a portfolio company of Domain Associates LLC, a venture capital firm with an exclusive focus on investing in life science companies, and RUSNANO, which initiatives to promote the Russian government’s policy of fostering hi-tech industries.

NovaMedica was formed to provide the development, marketing and operational capabilities needed to commercialize highly innovative next-generation products from the collaboration in Russia and the CIS. The company’s strategy is aimed at localizing production of a wide range of new medicines and technologies for the Russian market, including establishing screening and registration operations and innovative GMP-standard manufacturing facilities.

For more info please go to www.novamedica.com  

Skolkovo Foundation

Scientific Centre for Development and Commercialization of New Technologies "Skolkovo" (Skolkovo Foundation) - a non-profit organization established on the initiative of the President of Russian Federation in September 2010. The purpose of the Foundation - the mobilization of resources in Russia in the field of contemporary applied research, the creation of an enabling environment in which scientific development can be carried out in the five top-priority areas of technological development: energy and energy efficiency, aerospace, biomedicine, nuclear and computer technologies. The Skolkovo innovation ecosystem comprises the Skolkovo Institute of Science and Technology (Skoltech), corporate R&D centers, business incubators and accelerators, private seed and venture funds, and start-up companies, as well as residential space and social infrastructure and subsequent expansion to be applied in other innovative regions of Russia. Skolkovo is governed by a special law, which gives its resident companies special economic conditions for running their businesses. For more info please go to www.sk.ru